Phase I clinical trials as a therapeutic option for patients with metastatic renal cell carcinoma (mRCC).

Andrew W. Hahn, Omar Alhalabi, Funda Meric‐Bernstam, Aung Naing, Eric Jonasch, Pavlos Msaouel, Sarina A. Piha‐Paul, David S. Hong, Shubham Pant, Timothy A. Yap

Type: Article

Publication Date: 2020-05-20

Citations: 0

DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.5073

View Publication

Locations

Journal of Clinical Oncology - View

Similar Works

Action	Title	Year	Authors
+ PDF Chat	Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials	2020	Andrew W. Hahn Omar Alhalabi Pavlos Msaouel Funda Meric‐Bernstam Aung Naing Eric Jonasch Sarina A. Piha‐Paul David S. Hong Shubham Pant Timothy A. Yap
+	Is there a therapeutic benefit for patients participating in modern phase I trials?	2011	Mark N. Stein Anderson Tan Janice M. Mehnert Darlene Gibbon Robert S. DiPaola R. Moss Elizabeth Poplin Eric H. Rubin Biren Saraiya M. P. Kane
+ PDF Chat	Predicting Phase Iii Survival outcomes Using Phase Ii Trial Data In Nsclc and Rcc	2015	R. Macaulay Hon Lyn Tan
+	3 Questions on...The Role of Phase I Clinical Trials in Cancer	2017	Sarah DiGiulio
+	Phase I Cancer Clinical Trials	2012	Seung‐Ho Kang Chul Ahn
+	Phase I Cancer Clinical Trials	2018	Seung‐Ho Kang Chul Woo Ahn
+	Phase I Cancer Clinical Trials	2010	Seung‐Ho Kang Chul Ahn
+	Supplementary Tables 1 - 4, Figures 1 - 2 from Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer Drugs	2023	Denis L. Jardim Kenneth R. Hess Patricia LoRusso Razelle Kurzrock David S. Hong
+	Supplementary Tables 1 - 4, Figures 1 - 2 from Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer Drugs	2023	Denis L. Jardim Kenneth R. Hess Patricia LoRusso Razelle Kurzrock David S. Hong
+ PDF Chat	Phase I Cancer Clinical Trials	2015
+	Risks and benefits of phase I trials: Eighteen-year experience from a single institution.	2017	Audrey E. Kam Imran Chaudhary Mohammad H. Ghalib Umang Shah Umang Swami Dennis Yi‐Shin Kuo Caroline Hwang Tarek N. Elrafei Bruce Cohen Benjamin A. Gartrell
+	Predicting success in regulatory approval from phase I results.	2014	Laeeq Malik Alex Mejia Helen Parsons Benjamin Ehler Devalingam Mahalingam Andrew Brenner John Sarantopoulos Steven Weitman
+	Proportion of patients in phase I solid tumor oncology trials receiving treatments that are clinically efficacious.	2023	Carlos Muzlera Elena Elimova
+ PDF Chat	Dynamic change in the distribution of cancer types in oncology phase I trials	2019	Junya Sato K. Itahashi Tetsuro Shimizu Takahiko Koyama Shunsuke Kondo Yasuhiro Fujiwara N. Yamamoto
+	The Changing Landscape of Phase I Trials in Oncology	2015	Kit Man Wong Anna Capasso Sabine Eckhardt
+	Clinical benefits and risks of phase I oncology trials: experience from a single institution	2008	R. Gollamudi Bcy Wong Mohammad H. Ghalib Mohit Kumar Ketan Desai Imran Chaudhary Shruti Goel S. Mani
+ PDF Chat	Phase I Clinical Trials in Oncology	2020	Prasanth Ganesan
+	Risks and benefits of phase I trials: Twelve-years experience from a single institution.	2011	U. Swami M. H. Ghalib I. Chaudhary J. Y. Hou S. Aparo M. H. Einstein G. L. Goldberg T. N. Elrafei S. Gajavelli B. Cohen
+	Relationship between Progression-Free (PFS) and Overall Survival (OS) in I-Line Randomized Clinical Trials (RCT) for Advanced Renal Cell Carcinoma (RCC): Correlation and Power Analysis	2012	Emilio Bria Francesco Massari Francesca Maines Maria Bonomi Camillo Porta Sergio Bracarda F. Cognetti Diana Giannarelli Giampaolo Tortora Michèle Milella
+	Phase I Oncology Research	2008	Manish Agrawal Ezekiel J. Emanuel

Works That Cite This (0)

Action	Title	Year	Authors

Works Cited by This (0)

Action	Title	Year	Authors